Topos Bio, Inc.

SAN FRANCISCO, CA · Founded 2024 · CIK 0002050962 · Biotech · Private

Small molecule drugs targeting intrinsically disordered proteins

toposbio.ai →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$9.0M
1 Form D · Jan 2025
21 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$8,999,995
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2536ELIAS Animal Health, LLC—$2.4M
2537BIOIO, LLC——
2538EIKONIZO THERAPEUTICS, INC.—$2.4M
2539Topos Bio, Inc.—$9.0M
2540Addition Therapeutics—$28M
2541NBO Pharma Inc.—$7.6M
2542Apriori Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Ellen ChisaDirector
  • Amir KhosrowshahiDirector · Executive Officer · Promoter
  • Ryan ZarconeDirector · Executive Officer · Promoter

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.